Table 1.
Comparison of patients’ characteristics and imaging results between the presence (COVID+) and absence (COVID−) of a SARS-COV-2 infection
| COVID+ (n = 11) |
COVID− (n = 11) |
P value | |
|---|---|---|---|
| 18F-FDG PET indications | 0.03* | ||
| Initial diagnosis or follow-up of a cancer | 4 (36%) | 10 (91%) | |
| Suspicion of prosthesis infection, vasculitis, or endocarditis | 4 (36%) | 1 (9%) | |
| Part of workups of macrophage activation syndrome or pericarditis | 3 (28%) | – | |
| Age (years) | 72 ± 10 | 62 ± 15 | 0.09 |
| Female gender | 4 (36%) | 2 (18%) | 0.34 |
| Body mass index (kg.m−2) | 27.7 ± 5.8 | 23.3 ± 3.3 | 0.04* |
| Infectious symptoms | 8 (73%) | 8 (73%) | 1.00 |
| Delay from symptom onset (days) | 12 ± 5 | 11 ± 6 | 0.80 |
| C-Reactive Protein (mg.L−1)¥ | 36.8 ± 37.8 | 133.6 ± 139.3 | 0.20 |
| Extent of CT lung abnormality score | 11.5 ± 8.0 | 6.7 ± 7.2 | 0.16 |
| Presence of a GGO pattern by CT | 8 (73%) | 7 (64%) | 0.65 |
| Presence of a CPP pattern by CT | 7 (64%) | 7 (64%) | 1.00 |
| Presence of a CON pattern by CT | 3 (27%) | 7 (64%) | 0.09 |
| SUVmax of lung CT abnormalities | 3.7 ± 1.9 | 6.9 ± 4.1 | 0.03* |
| SUVmax in areas with CON, GGO or CPP lesions (n = 20/n = 19) | 3.0 ± 1.7 | 5.2 ± 3.8 | 0.03* |
| SUVmax in areas with CON lesions (n = 3/n = 7) | 3.7 ± 2.1 | 8.6 ± 3.6 | 0.07 |
| SUVmax in areas with GGO or CPP lesions (n = 17/n = 12) | 2.9 ± 1.7 | 3.2 ± 2.2 | 0.67 |
*: p < 0.05 for the comparison between COVID+ and COVID− patients
¥C-Reactive Protein (mg.L−1): C-Reactive Protein only available for 12 patients (7 COVID+ and 5 COVID−)
BMI: Body mass index; CON: pattern of consolidation by CT; GGO: pattern of Ground Glass Opacity by CT; CPP: Crazy-Paving pattern by CT; SUVmax: maximal standardized uptake value